Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XVRd in high-risk newly diagnosed multiple myeloma
ChiCTR2200062602Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: ATG-010 maximum tolerated dose, ATG-010 recommended phase II dose and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
selinexorbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200062602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062602.